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ABSTRACT
Mitochondrial diseases are severe and largely untreatable. Owing to
the many essential processes carried out by mitochondria and the
complex cellular systems that support these processes, these
diseases are diverse, pleiotropic, and challenging to study. Much of
our current understanding of mitochondrial function and dysfunction
comes from studies in the baker’s yeast Saccharomyces cerevisiae.
Because of its good fermenting capacity, S. cerevisiae can survive
mutations that inactivate oxidative phosphorylation, has the ability to
tolerate the complete loss of mitochondrial DNA (a property referred
to as ‘petite-positivity’), and is amenable to mitochondrial and nuclear
genome manipulation. These attributes make it an excellent model
system for studying and resolving the molecular basis of numerous
mitochondrial diseases. Here, we review the invaluable insights this
model organism has yielded about diseases caused bymitochondrial
dysfunction, which ranges from primary defects in oxidative
phosphorylation to metabolic disorders, as well as dysfunctions in
maintaining the genome or in the dynamics of mitochondria. Owing to
the high level of functional conservation between yeast and human
mitochondrial genes, several yeast species have been instrumental in
revealing the molecular mechanisms of pathogenic human
mitochondrial gene mutations. Importantly, such insights have
pointed to potential therapeutic targets, as have genetic and
chemical screens using yeast.
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Introduction
Mitochondria provide energy to the cells by generating adenosine
triphosphate (ATP) molecules through the process of oxidative
phosphorylation (OXPHOS) in eukaryotes, which involves the
oxidation of nutrients (see Box 1) (Saraste, 1999). They also carry
out numerous other conserved vital functions, including lipid and
steroid synthesis (Horvath and Daum, 2013), and the biosynthesis of
iron-sulfur clusters and heme (Lill et al., 2012; Box 2), among many
others (Fig. 1) (Galluzzi et al., 2012). Mitochondria are organized as
a network of interconnected double-membrane tubules that is
continuously remodeled by fusion and fission (Chen and Chan,
2009; Westermann, 2010). The outer and inner membranes (OM
and IM, respectively) delineate two aqueous compartments: the
intermembrane space (IMS) and matrix. The IM has a boundary
domain beneath the OM, and cristae domains that project internally
into the matrix (see Fig. 1).
Mitochondrial genomes are remnants of an ancestral prokaryotic
genome, most of which has been lost or transferred to the nucleus
during the evolution of eukaryotes (Gray, 2014; Gray et al., 1999).
Thus, most of the genes required for mitochondrial structure and
function (>99%) are located in the nucleus of the cell [the nuclear
DNA (nDNA)] and a tiny proportion is located in mitochondria
(mtDNA). nDNA-encoded mitochondrial proteins are synthesized
by cytoplasmic ribosomes and imported into mitochondria (Dolezal
et al., 2006; Harbauer et al., 2014; Neupert and Herrmann, 2007).
The maintenance of a separate genetic system in mitochondria is
costly because it requires numerous proteins for:mtDNA replication,
repair, recombination and transcription; mitochondrial RNA
(mtRNA) processing and translation; and for gene regulation in
the organelle (Fox, 2012; Herrmann et al., 2013; Peralta et al., 2012).
Moreover, nuclear-mitochondrial interactions need fine-tuning to
coordinate the expression of both nuclear and mitochondrial
genomes (Frechin et al., 2014).
Given the structural and functional complexity of mitochondria,
it is not surprising that mitochondrial dysfunction has been
implicated in a broad spectrum of human diseases. The first case
was reported in 1959 by Roth Luft, who described a young woman
suffering from a hypermetabolic disorder in the form of excessive
mitochondrial respiration not effectively coupled to ATP production
(Ernster et al., 1959). Since then, more than 150 distinct genetic
mitochondrial dysfunction syndromes have been described, most of
which arise from disorders affecting the energetic function of
mitochondria. These diseases affect at least 1 in 5000 live human
births (Skladal et al., 2003) and can present either in infancy or
adulthood, in a multisystemic or highly tissue-specific manner.
Typical clinical traits include visual and/or hearing defects,
encephalopathies, cardiomyopathies, myopathies, diabetes, and
liver and renal dysfunctions (DiMauro and Schon, 2003; Vafai
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and Mootha, 2012; Zeviani and Carelli, 2007). Many known cases
result from alterations in mtDNA, which occur as a result of this
DNA’s high susceptibility to mutations because of the nearby
production of reactive oxygen species (ROS; Box 2) and the poor
effectiveness of the mtDNA repair system (Wallace, 2010).
Mitochondria are also believed to have a role in common
disorders, such as diabetes, obesity, age-related neurodegenerative
and cardiovascular diseases, cancer, and probably also the aging
process owing to a progressive decline of mitochondrial function
during life (Koopman et al., 2013; Wallace, 2012).
Despite considerable progress in defining the pathogenesis of
mitochondrial disorders over the last 20 years, there are still no
effective therapies to treat them. Although gene-therapy approaches
have been envisioned for treating some mitochondrial diseases
(DiMauro et al., 2006; Schon et al., 2010), a strategy that would be
easier to implement is effective metabolic or pharmacological
treatment (Andreux et al., 2013; Wallace et al., 2010). Many
pharmacological agents have been assessed as therapies for
mitochondrial diseases, including vitamins or cofactors involved
in energy metabolism, metabolic intermediates, enzyme activators
and anti-oxidants, but none has so far shown conclusive therapeutic
benefit (Kerr, 2010, 2013). Thus, there is an urgent need to develop
new drugs to treat these diseases.
Recent work, reviewed here, has proven that yeast is a valuable
system in which to model mitochondrial disorders and identify new
compounds with therapeutic potential. As the organism in which
mtDNA was first discovered (Corneo et al., 1966; Ephrussi and
Slonimski, 1955; Mounolou et al., 1966), Saccharomyces cerevisiae
has played an essential role in building our understanding of
mitochondrial function. This includes providing details of
mitochondrial regulation, its key processes and components, and
their interplaywith cellular functions.Not only has this understanding
been important for studies of these processes in humans and other
eukaryotes, but the methodologies developed in yeast have also
enabled detailed investigations of pathogenic mutations implicated in
mitochondrial diseases. The success of such studies with this
unicellular and relatively simple eukaryote hinges on several
factors: the high conservation of mitochondrial function, the
exceptionally thorough annotation of the yeast genome, and the
tractability of yeast for manipulations of the mitochondrial and
nuclear genomes and for genetic and chemical screens.
Mitochondrial structure and function
We begin this Review by providing a brief overview of mitochondrial
processes and components that have been implicated in human
diseases.
The OXPHOS system
The energy-transducing system of mitochondria comprises multi-
subunit complexes (CI-CV) embedded within the mitochondrial
IM, which, together with cytochrome c and ubiquinone (see Box 2
for a glossary of terms), form what is usually called the OXPHOS
system (see Box 1, and Figs 1, 2). CI-IV transfer electrons to
oxygen, a process that is coupled to the pumping of protons out of
the mitochondrial matrix; protons are transported back into the
matrix by CV (ATP synthase), which is coupled to ATP synthesis
from ADP and inorganic phosphate. The OXPHOS system contains
approximately 90 different structural protein subunits [of which 13
are encoded by the mtDNA in humans (Box 3)] and 24 redox groups
[13 FeS, one flavin mononucleotide (FMN), one flavine adenine
(FAD), seven hemes and two Cu2+; see Box 2 and Fig. 2].
Assembling this system is a sophisticated process involving dozens
of proteins with highly specific actions (Devenish et al., 2008; Fox,
2012; Ghezzi and Zeviani, 2012; Mick et al., 2011; Nouws et al.,
2012; Rak et al., 2009; Rutter et al., 2010; Smith et al., 2012; Vogel
et al., 2007; Zara et al., 2009).
Mitochondrial protein import
After their synthesis in the cytosol, nDNA-encoded mitochondrial
proteins must be imported and sorted to their respective intra-
mitochondrial locations: the outer membrane (OM), the
intermembrane space (IMS), the inner membrane (IM) or the
matrix. This process is mediated by a multi-component machinery
[reviewed in Chacinska et al., 2009; Dolezal et al., 2006; Fox, 2012;
Harbauer et al., 2014; see also Fig. 1 and its legend], the activity of
which is modulated at multiple levels to regulate biogenesis,
composition and turnover of the organelle in connection with
cellular metabolism, signaling and stress (Harbauer et al., 2014).
mtDNA maintenance and expression
The human mtDNA genome is inherited through the maternal
lineage (Giles et al., 1980). It is packaged into structures termed
nucleoids (Bogenhagen, 2012; Kukat and Larsson, 2013) – which
frequently contain a single copy of mtDNA (Kukat et al., 2011) –
that contain proteins involved in mtDNA replication, maintenance,
repair and recombination (Box 3, Fig. 1). Dozens of nuclear-
encoded proteins are additionally required for mitochondrial protein
synthesis. Because all the intraorganellar-synthesized proteins are
very hydrophobic, they can have different chaperone requirements
than soluble proteins synthesized on cytosolic ribosomes. Specific
subunits of the mitochondrial ribosome (MRPL39, MRPL44 and
MRPL45) have evolved to facilitate the accurate co-translational
insertion of the nascent peptide into the IM together with the help of
various factors (Greber et al., 2014). In yeast mitochondria,
messenger RNA (mRNA) recognition by the ribosome utilizes the
untranslated region upstream of the start codon (5′UTR) to establish
interactions with gene-specific IM-located translational activators
(Fox, 2012). Mammalian mitochondrial mRNAs do not have 5′
Box 1. Mitochondrial oxidative phosphorylation
(OXPHOS)
As a first step in oxidative phosphorylation, fuel molecules (such as
monosaccharides and fatty acids) are transferred to nicotinamide (NAD)
and flavine adenine (FAD) nucleotides, through glycolysis, the Krebs
cycle and β-oxidation (see Box 2 for a glossary of terms), and are then
moved to oxygen through an electron transport chain (ETC) (Box 2)
typically made of four protein complexes (CI-CIV) embedded within the
mitochondrial inner membrane (IM). The free energy released by the
electron flow at the level of CI, CIII and CIV is used to maintain an
electrochemical potential (ΔµH) (Box 2), composed of an electrical
gradient (ΔΨ) and a pH gradient, across the mitochondrial IM. This
membrane potential drives ATP synthesis from ADP and inorganic
phosphate (Pi) through the activity of an enzyme called F1FO-ATP
synthase (CV) (Fig. 2). Most of the ATP produced by CV is exchanged
against cytosolic ADP through a specific adenine nucleotide carrier
(ANC), to supply the rest of the cell with energy and to maintain the ADP
phosphorylation capacity of mitochondria (Fig. 2). ETC form large and
stable supra-molecular structures, called respirasomes (Boekema and
Braun, 2007; Dudkina et al., 2011; Winge, 2012; Wittig and Schagger,
2009), which enhance substrate channeling and reduce the production
of reactive oxygen species (ROS; see Box 2) caused by the diversion of
electrons from their normal pathway to oxygen. CV also forms oligomeric
structures in the form of ribbons of dimeric units that are important for the
formation of mitochondrial cristae (Fig. 1) (Giraud et al., 2002;
Habersetzer et al., 2013; Paumard et al., 2002; Strauss et al., 2008).
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UTRs; as-yet-unknown alternative mechanisms must therefore be
responsible for their recognition by the ribosome. So far, only a
limited number of factors involved in mitochondrial ribosome
biogenesis have been identified (Dennerlein et al., 2010; Kehrein
et al., 2015; Metodiev et al., 2009; Tu and Barrientos, 2015). An
interesting recent development indicates that the mitochondrial
ribosomal RNAs (mt-rRNAs) assemble with mitochondrial
ribosomal proteins immediately after, or concomitant with, their
synthesis (Bogenhagen et al., 2014; Dalla Rosa et al., 2014).
Protein and organelle quality controls
Co-ordinating the expression of nDNA and mtDNA is of crucial
importance to avoid the accumulation of unassembled OXPHOS
subunits, which are prone tomisfolding or aggregation. Mitochondria
also have to deal with the production of deleterious ROS, created by
the OXPHOS system, which damage biomolecules and ultimately
lead to the depolarization of the IM and to apoptosis (Martinou and
Youle, 2011; Wang and Youle, 2009). Mitochondria have therefore
evolved quality-control mechanisms to remove damaged proteins and
to sequester and eliminate damaged organelles (Anand et al., 2013;
Baker and Haynes, 2011; Baker et al., 2011) (see Fig. 1). A cohort of
mitochondrial proteases enables the clearing of damaged proteins
from the IM [m-AAA [AAA (ATPase Associated with diverse
Activities) protease that is active at the matrix side of the
mitochondrial membrane), i-AAA (protrudes into the IMS) and
OMA1 (has overlapping activity with the m-AAA protease)] and the
matrix [Lon (see Box 2) and ClpXP]. Nuclear-encodedmitochondrial
proteins that become mistargeted or misfolded en route to the
organelle are removed by the cytosolic ubiquitin-proteasome system
(UPS) (Livnat-LevanonandGlickman, 2011),which can also degrade
proteins residing in the OM (Karbowski and Youle, 2011).
Mitochondria also undergo fusion and fission events to enable them
tomaintain their shape, number, functional properties and integrity of
their genome (Osman et al., 2015). This activity is mediated by
evolutionary conserved GTPases of the dynamin superfamily located
in the mitochondrial membranes [dynamin-related protein 1 (DRP1),
mitofusin 1/2 (MFN1/2) and optic atrophy 1 (OPA1); see Fig. 2].
Fusion allows mitochondria that are deficient in some components to
be replenished with healthy organelles. Under certain stress
conditions, the mitochondrial network becomes hyper-fused, which
protects mitochondria against autophagy (see Box 2) and maintains
cellular ATP production (Rambold et al., 2011). Severely damaged
mitochondria that are unable to sufficiently energize the IM can no
longer fuse, which results in their separation from the mitochondrial
Box 2. Glossary of terms
Aminoaciduria:presenceof aminoacids in theurine that canbe increasedby
metabolic disorders, chronic liver disease or renal disorders.
Aminoacyl tRNA synthetase: an enzyme attaching the appropriate amino
acid onto its tRNA, an essential step in the synthesis of proteins.
Autophagy: a mechanism enabling the cell to degrade and recycle
unnecessary or dysfunctional components.
β-oxidation: the process that transforms fatty acids into acetyl-CoA, which
is then oxidized by the Krebs cycle.
Cholestasis: a condition in which bile cannot flow from the liver to the
duodenum.
Citrate: conjugate base of citric acid, which is an important intermediate in
the citric acid (or Krebs) cycle.
Corpus callosum: a wide, flat bundle of neural fibers beneath the cortex
that connects the left and right cerebral hemispheres.
Cybrid (cytoplasmic hybrid): a eukaryotic cell line produced by the fusion
of a whole cell lacking mitochondrial (mt)DNA (ρ0) with an enucleated cell
(cytoplast), which can be used to investigate the pathogenesis of mtDNA in
individuals with a mitochondrial disease in a control nuclear genetic
background.
Cyclic neutropenia: a disorder causing frequent infections due to a
shortage of neutrophils, which are a type of white blood cell that
play a role in inflammation and in fighting pathogens such as bacteria
and viruses.
Cytochrome c: a soluble hemoprotein in the intermembrane space of
mitochondria that transfers electrons from CIII to CIV.
Electrochemical potential (ΔµH): a gradient of electrical potential and
chemical concentration enabling themovement of ions (e.g. protons) across
a biological membrane.
Electron transport chain (ETC): a multicomponent system – usually a
series of multi-subunit protein complexes – that transfers electrons from one
molecule to another.
Flavine adenine dinucleotide (FAD): a redox cofactor involved in the
transfer of electrons from one molecule to another.
Glycolysis: a metabolic pathway that converts glucose into pyruvate.
Heme a3: a coordination complex attached to CIV that consists of an iron
atom chelated by porphyrin and which can bind dioxygen.
Heteroplasmy: a term used in genetics to describemammalian cells whose
copies of mtDNA are not all identical, which is an important factor in
considering the severity of diseases caused by mutations in the
mitochondrial genome. Mitochondrial heteroplasmy in disease is the co-
existence within a cell of wild-type and mutated mitochondrial (mt)DNA;
beyond a certain threshold mutated mtDNA results in deleterious
physiological consequences.
Homoplasmy: a term used in genetics to describe amammalian cell whose
copies of mtDNA are all identical, either normal or mutated.
Hyperornithinemia-hyperammonemia-homocitrullinuria (HHH): a
metabolic disorder that can result in chronic neurocognitive deficits
(including developmental delay, ataxia, spasticity, learning disabilities and
seizures), acute encephalopathy and chronic liver dysfunction.
Intergenic region: a stretch of DNA located between genes.
Intron: any nucleotide sequence within a gene that is removed by RNA
splicing.
Iron-sulfur (Fe-S) proteins: proteins characterized by the presence of iron-
sulfur clusters that are used in oxidation-reduction reactions, such as
proteins belonging to complexes I, II and III of the mitochondrial electron
transport chain (ETC).
Krebs cycle: also known as the citric acid cycle or the tricarboxylic cycle
(TCA); a series of chemical reactions enabling aerobic organisms to
generate energy through the oxidation of acetate derived from
carbohydrates.
Leigh syndrome: a rare inherited neurometabolic disorder affecting the
central nervous system.
Lon: ATP-dependent protease (also called protease La) whose name is
derived from the phenotype ofEscherichiacoli lon genemutants that form long
(hence the name Lon) undivided filaments upon UV radiation.
Mitophagy: the process by which mitochondria are degraded via the
autophagy pathway.
Neuropathy, ataxia and retinitis pigmentosa (NARP): a rare diseasewith
maternal inheritance that chiefly affects the nervous system and is
characterized by various symptoms such as pain in the arms and legs,
muscle weakness, loss of vision, and problems with balance and
coordination.
Nicotinamide adenine nucleotide (NAD): a redox cofactor found in all
living cells that is involved in the transfer of electrons from one molecule to
another.
Ornithine: an amino acid that plays a role in the urea cycle, which allows the
disposal of excess nitrogen.
Reactive oxygen species (ROS): chemically reactive oxygen-containing
molecules that can damage any type of biomolecule.
Ubiquinone (coenzymeQ): a hydrophobic component with highmobility in
biological membranes that transfers electrons from CI and CII to CIII in
mitochondria.
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network and subsequent degradation by autophagy, a phenomenon
called mitophagy (see Box 2) (Kim et al., 2007; Sauvanet et al., 2012;
Twig et al., 2008). A central role for the autophagic removal of
depolarizedmitochondria has been assigned to the E3 ubiquitin ligase
Parkin andPTEN-inducedkinase1 (PINK1): functionalmitochondria
efficiently import and degrade PINK1; when the IM potential
collapses, PINK1 accumulates at the mitochondrial surface, where it
recruits Parkin to initiate mitophagy (Matsuda et al., 2010; Narendra
et al., 2010). Previously unknown lines of defense against
mitochondrial damage are emerging, like the delivery of selective
mitochondrial cargo to lysosomes as an early response to oxidative
stress (Soubannier et al., 2012).
In addition to their roles in degrading misfolded or oxidatively
damaged proteins, mitochondrial proteases have key regulatory
functions. For example, the Lon protease prevents excessive
accumulation of the mitochondrial transcription factor TFAM.
Excessive accumulation of TFAM relative to mtDNA copy number
inhibits transcription (Matsushima et al., 2010). The Lon protease
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Fig. 1. Overview of mitochondrial processes and components. This is a schematic cross-section of a human mitochondrion, showing a number of
components involved in mitochondrial function. (1) Import and sorting of proteins of nuclear origin: the translocase of the outer membrane (TOM) complex
mediates translocation of proteins across or into the outer membrane (OM); sorting and assembly machinery (SAM; also known as TOB) facilitates protein
insertion from the intermembrane space (IMS) into the OM; TIM23 takes in proteins with a cleavable mitochondrial targeting sequence (MTS), directing them
either into the matrix (M) (when associated to PAM) or the inner membrane (IM) (when associated to Tim21); Twin-cys (the so-called mitochondrial disulfide relay
system) mediates, in a redox-dependent manner, the delivery into the IMS of proteins containing specific cysteine motifs; TIM22, together with small soluble
proteins in the IMS (called Tim), delivers into the IM the proteins of the so-called mitochondrial carrier family (MCF) that lack a cleavable MTS; OXA1 helps the
insertion of proteins from the matrix into the IM. (2) Mitochondrial quality control: misfolded and damaged mitochondrial proteins and organelles are eliminated by
proteases and chaperones present in the IM (i-AAA, m-AAA) or the matrix (Lon, ClpXP) by the cytosolic ubiquitin proteasome system (UPS), and by the PINK1
and Parkin proteins at the surface of mitochondria. Fusion (which is mediated by MNF1, MNF2, OPA1L and OPA1S) and fission (mediated by DRP1) of
mitochondria contribute also to mitochondrial quality surveillance. (3) mtDNA maintenance and expression: mtDNA is packaged into structures called nucleoids
that contain proteins involved in mtDNA maintenance (PolG, Twinkle, mt-SSB), RNA synthesis (TFAM), and the processing of RNAs into messenger (mRNA),
transfer (tRNA) and ribosomal (rRNA) RNAs, which are then used to translate themtDNA-encoded proteins onmitochondrial ribosomes. (4) OXPHOS assembly:
the nDNA-encoded subunits of the OXPHOS system (Nuc OXPHOS subunits; CI-V) assemble with their partner subunits of mitochondrial origin (Mt OXPHOS
subunits; all except CII, which is entirely encoded by nDNA) together with their redox prosthetic groups (heme and FeS, which are in part synthetized in the
mitochondria, and Cu2+). CI-IV together with ubiquinone (Q) and cytochrome c (c) transfer electrons to oxygen from reduced cofactors (NADH, FADH) produced
by the Krebs cycle, which is coupled to the pumping of protons out of the matrix. The protons are transported back into the matrix by CV, which is coupled to ATP
synthesis from ADP and inorganic phosphate (Pi) (see Fig. 2 for details). (5) Transport of metabolites: systems in the OM (VDAC; also known as porin) and
IM [MCF (mitochondrial carrier family)] enable the transport of small solutes and ions into and outside the organelle. Parts of the IM protrude into the matrix,
forming the cristae, at the basis of which narrow tubular structures termed ‘cristae junctions’ are maintained by proteins of the mitochondrial inner membrane
organizing system (MINOS) complex.
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additionally affects the biosynthesis of steroid hormones by
degrading a protein (StAR) that facilitates cholesterol transfer
from the outer to the inner mitochondrial membranes, making it
available for steroid hormone synthesis (Lin et al., 1995). A key
regulatory function of m-AAA protease is the processing of the
precursor form of theMrp32 subunit of the mitochondrial ribosome,
a prerequisite for its assembly and hence for mitochondrial
translation (Bonn et al., 2011). In addition to its clearance activity
of damaged proteins, the i-AAA protease has a central role in the
maintenance of the lipid composition of mitochondrial membranes
(Nebauer et al., 2007; Potting et al., 2010).
Transport of metabolites
Because the IM is largely impermeable to solutes and ions, proper
mitochondrial function requires a cohort of systems within this
membrane for the import into thematrix of numerous smallmolecules,
such as ADP and inorganic phosphate for oxidative phosphorylation
and substrates of the Krebs cycle (Box 2), as well as for the export into
the cytosol of a number of molecules produced inside the organelle,
such as ATP and heme-biosynthesis intermediates. Most of this
transport is mediated by structurally related proteins referred to as
mitochondrial carriers (MCs) (Palmieri, 2014).
Yeast as amodel for studying humanmitochondrial diseases
Much of what we know about mitochondria originally came from
studies in S. cerevisiae, which was established as a genetic system for
studying mitochondria 60 years ago, by Boris Ephrussi and Piotr
Slonimski, owing to its ability to survive mutations that inactivate
OXPHOS when provided with fermentable sugars (Ephrussi and
Slonimski, 1955). The first characterized respiratory-deficient
S. cerevisiae mutation (ρ−/ρ0) revealed that respiration is controlled
in yeast by a non-mendelian genetic element, the ρ factor, which was
found a couple of years later to be a small DNA molecule located in
the mitochondrion (mtDNA) (Corneo et al., 1966; Mounolou et al.,
1966). Because of the limited coding capacity of mtDNA, it was
rapidly realized that most of the fundamental processes involved in
mitochondrial biogenesis must depend on the expression of genes
located in nDNA. This was confirmed by Alexander Tzagoloff, who
established more than 30 years ago the existence of at least 200
genetically distinct nuclear loci required for the growth of yeast cells
on non-fermentable substrates, many of which were shown to control
the replication and expression of mitochondrial genes (Tzagoloff
and Dieckmann, 1990). The sequencing of the S. cerevisiae genome
and the construction of a whole-genome deletion-mutant collection
identified 265 previously unknown nuclear genes required for
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Fig. 2. Mammalian versus yeast OXPHOS system. The figure shows the main enzymatic systems involved in mitochondrial oxidative phosphorylation
(OXPHOS) in yeast and mammals. In mammals (top), complexes I-IV together with ubiquinone (Q) and cytochrome c (cyt c) transfer electrons to oxygen from the
NADH and succinate produced by the Krebs cycle. These transfers are, at the level of complexes I, III and IV, coupled to proton translocation from the matrix into
the intermembrane space (IMS). The resulting proton gradient across the inner mitochondrial membrane (IM) is used by complex V (F1Fo ATP synthase) to
produce ATP from ADP and inorganic phosphate (Pi). Part of the ATP produced in the matrix is exchanged against cytosolic ADP by the ADP/ATP translocase
(ANT) to provide the whole cell with energy and to maintain the ADP phosphorylation capacity of mitochondria. The OXPHOS system of S. cerevisiae (bottom) is
highly similar to the mammalian system except that complex I is replaced by a non-proton-translocating NADH dehydrogenase (Ndi1p) at the inner side of the IM.
There are also in S. cerevisiae two NADH dehydrogenases on the external side of the IM (Nde1p, Nde2p) that deliver electrons at the level of ubiquinone. The
protein structures are from the Protein Data Bank (PDB) and are at the same scale (indicated by the scale bar).
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optimal respiratory growth (Steinmetz et al., 2002). Proteomic
analyses have also been used to explore the protein composition of
this organelle. Mass spectrometry analyses of highly pure yeast
mitochondria identified 850 proteins and led to an estimation that
there are in total about 1000 protein species in yeast mitochondria
(Prokisch et al., 2004; Reinders et al., 2006). Remarkably, a similar
number of mitochondrial proteins was estimated from the analysis of
14 different mouse tissues, of which more than 50% had a yeast
homolog (Pagliarini et al., 2008), which indicated that the
mitochondria of single-celled organisms are as complex, and are
highly similar, to those found in individual tissues of higher
eukaryotes. Further analyses have revealed that the mammalian
mitochondrial proteome likely contains 1500 proteins, of which 1100
have been identified (Rhee et al., 2013). Tissue diversity is a likely
reason for the larger size of the mitochondrial proteome in mammals
compared to yeast. As described in the next section, the high
similarities between yeast and human mitochondria considerably
helped the study of mitochondrial diseases.
Yeast models of human diseases caused by mtDNA point mutations
Currently, more than 250 point mutations in human mtDNA that are
proven or suspected to be pathogenic have been identified (http://
www.mitomap.org). Mutations in protein-encoding mitochondrial
genes primarily (and possibly only) affect the energy-transducing
complexes towhich they belong, whereas mutations in mitochondrial
transfer RNA (mt-tRNA) genes have more pleiotropic consequences
by impairing mitochondrial protein synthesis. mtDNA point
mutations are often heteroplasmic (see Box 2), and are usually
considered as being highly recessive (relative to the corresponding
wild-type alleles), which can render it difficult to evaluate how they
affect mitochondrial functions. Furthermore, given the high
mutational rate of the mitochondrial genome and the presence of
numerous family or population-specific polymorphisms, it can be
difficult to distinguish between a neutral mtDNA variant and a
disease-causing mutation. Also, multiple studies have determined
that the effects of deleteriousmtDNAmutationsmight be exacerbated
by mtDNA nucleotide changes that are not pathogenic per se and by
unknown factors in nuclear genetic background, i.e. so-called
modifier genes (Cai et al., 2008; Swalwell et al., 2008).
Owing to the absence of methods to mutagenize the
mitochondrial genomes of mammals, S. cerevisiae has been
utilized as an alternative model to investigate mtDNA mutations
found in patients. Mitochondrial genetic transformation can be
achieved in S. cerevisiae in a highly controlled fashion, by the
biolistic delivery (transfection by bombardment with DNA-coated
gold particles using a ‘gene gun’) into mitochondria of in-vitro-
made mutated mtDNA fragments, followed by their integration into
wild-type mtDNA by homologous DNA recombination (Bonnefoy
and Fox, 2001) (Fig. 3). Being unable to stably maintain
heteroplasmic mtDNA (Okamoto et al., 1998), it is relatively easy
to obtain yeast homoplasmic populations in which all mtDNA
molecules carry a mutation of interest. Several groups have
exploited these attributes to study various pathogenic mtDNA
mutations – for example, in the genes encoding subunits of
complexes III (cytochrome b) and IV (COXI, COXIII) (Meunier,
2001; Meunier et al., 2013), and in mt-tRNA genes (Feuermann
et al., 2003; Montanari et al., 2008), which have helped to better
define the functional consequences of these mutations. We similarly
investigated seven mutations (T9176G, T8851C, T8993G, T9191C,
T9176C, T8993C and T9185C) of the mitochondrial ATP6 gene
found in individuals with neuropathy, ataxia and retinitis
pigmentosa (NARP; see Box 2), Leigh syndrome (LS; see Box 2)
or bilateral striatal lesions of childhood (BSLC) (Kabala et al., 2014;
Kucharczyk et al., 2010, 2013, 2009a,b; Rak et al., 2007). All these
mutations significantly decrease the rate of mitochondrial ATP
synthesis in yeast, by 30 to >95% compared with the wild type. Our
study of T8851C has confirmed its previously uncertain
pathogenicity by revealing a block in the proton-translocating
domain of ATP synthase (Kucharczyk et al., 2013). Although only a
few cases of this mutation have been reported in patients, these
results support that it is responsible for the BSLC disorder and
premature death of affected individuals. We have also shown that
the T9176G mutation severely impedes the incorporation of the
protein encoded by the ATP6 gene (which is referred to as subunit a
or subunit 6) into yeast ATP synthase (Kucharczyk et al., 2009b),
and evidence for similar defects has been reported in skin fibroblasts
from patients carrying this mutation (Carrozzo et al., 2001).
Importantly, these findings in yeast correspond to the reported
severity of these mutations in humans, which likely reflects a high
level of evolutionary conservation within the regions of subunit a/6
that they affect (Baracca et al., 2000, 2007; Carrozzo et al., 2000,
2004; Cortes-Hernandez et al., 2007; De Meirleir et al., 1995;
Dionisi-Vici et al., 1998; Houstek et al., 2006;Mattiazzi et al., 2004;
Morava et al., 2006).
Yeast and nDNA-based mitochondrial diseases
The first nuclear mutation responsible for a mitochondrial disease
was discovered in 1995, in the subunit A of CII (SDHA), in two
Box 3. The human mtDNA genome
The human mitochondrial genome is a compact, double-stranded,
circular DNAmolecule of 16,569 bp that encodes 13 energy-transducing
proteins [seven CI subunits (ND1, ND2, ND3, ND4, ND4L, ND5 and
ND6), one CIII subunit (cytochrome b), three CIV subunits (COX1,
COX2, COX3) and two CV subunits (ATP6, ATP8)], and 22 tRNAs and
two rRNAs that are required for protein synthesis inside the organelle
(Andrews et al., 1999). The human mtDNA contains no introns and
almost no intergenic sequences (see Box 2 for a glossary of terms), with
the exception of the 1.1-kb displacement loop (D-loop) where
transcriptional promoters and at least one of the proposed replication
origins (OH) are located. Core components of the human mtDNA
replication machinery include the mitochondrial γ polymerase (POLG),
consisting of a catalytic subunit with 5′-3′ exonuclease activity (PolgA)
and a processivity subunit (PolgB), a protein with 5′-3′ DNA helicase
activity (Twinkle) and single-stranded binding protein (mt-SSB) (Holt and
Reyes, 2012; Rotig and Poulton, 2009). Most of the mtDNA genes are
transcribed as almost genome-length polycistronic transcripts (see
Box 2) that are next processed to produce individual mRNA and tRNA
molecules. Core components of the mitochondrial transcription
machinery include RNA polymerase (POLRMT), the transcription
activator A (TFAM), the transcription factor TFB2M (transcription factor
B2, mitochondrial) and the termination factor mTERF (mitochondrial
transcription termination factor) (Bestwick andShadel, 2013). Excision of
tRNAs from polycistronic transcripts involves two RNases, P and Z
(Holzmann et al., 2008; Takaku et al., 2003). Most mRNAs are
polyadenylated by MTPAP [mitochondrial poly(A) polymerase]
(Tomecki et al., 2004), which is believed to regulate their stability and
is often required to generate their stop codon (Nagaike et al., 2005;
Wydro et al., 2010). Proteins involved in mitochondrial protein synthesis
include: ribosomal proteins, aminoacyl tRNA synthetases, mt-tRNA
modification enzymes, two initiation factors (IF2 and IF3), three
elongation factors (EFG1, EFTs and EFTu), at least one termination
release factor (mtRF1), the translation regulator PTCD3
(pentatricopeptide repeat domain 3), the ribosome recycling factors
mtRFF and EFG2, and the methionine aminopeptidase MAP1D, which
removes N-terminal methionine (Christian and Spremulli, 2012;
Lightowlers et al., 2014).
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siblings affected with LS (Bourgeron et al., 1995). Since then, over
150 nuclear genes involved in mitochondrial diseases have been
identified (Calvo et al., 2010; Koopman et al., 2012; Vafai and
Mootha, 2012), 70% of which are conserved in yeast (see
supplementary material Table S1). As we discuss below, the
similarities between yeast and human mitochondria, and the
experimental benefits of the yeast system, have helped to resolve
the genetic and biochemical underpinnings of numerous
mitochondrial diseases with a nuclear genetic origin.
Diseases caused by OXPHOS assembly defects
After the discoveryof theyeastATP12gene and its role in the assembly
of the catalytic head ofCV (Ackerman andTzagoloff, 1990), sequence
comparisons identified a similar gene in human cDNA databases
(called ATPAF2) that proved to function like its yeast counterpart, as
tested by heterologous complementation (Wang et al., 2001). A
mutation in ATPAF2was subsequently found as being responsible for
the death of a 14-month-old girl who had severe neurological defects
due to a low CV content (De Meirleir et al., 2004).
Similarly, after the discovery of the yeast proteins Bcs1p [full
name: ubiquinol-cytochrome c reductase (bc1) synthesis] (Cruciat
et al., 1999) and Mzm1p (mitochondrial zinc maintenance) (Cui
et al., 2012) as being required for the maturation and/or insertion of
the Rieske iron-sulfur protein (Rip1) into CIII, the homologous
human genes, BCS1L and MZM1L, were considered as obvious
candidates in individuals with nDNA-based CIII-assembly defects.
Indeed, BCS1L (de Lonlay et al., 2001) and MZM1L (Invernizzi
et al., 2013) mutations were found in such individuals from
unrelated families, and complementation assays in yeast supported
the deleterious nature of several of them (Ostojic et al., 2013).
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Fig. 3. Construction of yeast models of a human mtDNA pathogenic mutation. Schematic of the steps used to create a yeast model of a mutation of the
human mitochondrial ATP6 gene, which causes neuropathy ataxia retinitis pigmentosa (NARP) syndrome. (A) In this approach, a plasmid containing a mutant
version of the yeast ATP6 gene that carries the NARP-associated mutation is created (ATP6-NARP). This is introduced into the mitochondria of a ρ0 arg8Δ kar1
strain, which is devoid of mtDNA (ρ0), has a null allele of the nuclearARG8 gene (arg8Δ) and amutation (kar1) that strongly delays nuclear fusion, which allows the
transfer of mtDNA from one nuclear haploid background to another (Conde and Fink, 1976). (B) The resulting ρ− synthetic strain, which fails to grow in the absence
of external arginine (ARG−), is crossed with (C) an arginine prototrophic (ARG+) strain that contains wild-type (ρ+) mtDNA but is deleted forATP6 (atp6Δ).ARG8m
is amitochondrial version of a nuclear gene (ARG8) and encodes a yeast mitochondrial protein involved in arginine biosynthesis (Steele et al., 1996). (D) Because
the ARG8m clone used to delete ATP6 is flanked on each side by ∼100 bp of the ATP6 locus, homologous recombination (E) can mediate the replacement of
ARG8m with the ATP6-NARP gene. (F) Mitotic segregation then produces ρ+ cells with the NARP-associated ATP6mutation in a pure (homoplasmic) form that
can be identified by virtue of their inability to grow in the absence of arginine.
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Another example of a protein involved in OXPHOS assembly is
Sdh5p, a conserved protein of unknown function identified in the
yeast mitochondrial proteome (Sickmann et al., 2003); this protein
is called SDHAF2 (succinate dehydrogenase assembly factor 2) in
humans. It proved to be necessary and sufficient for the attachment
of FAD (see Box 2) in CII (Hao et al., 2009), and the human
homolog was subsequently shown to interact with CII and was able
to rescue the flavination of the yeast enzyme in an sdh5Δ deletion
mutant, suggesting functional conservation. Based on the causal
relationship of loss of CII activity with a rare neuroendocrine tumor
called paraganglioma (PGL), the human SDHAF2 gene was
screened for mutations in such affected individuals. One indeed
had a mutation in this gene and the mutated gene was unable to
complement yeast sdh5Δ strains, strongly suggesting that the
mutation was causative.
Yeast has also helped to resolve the most common cause of LS,
which is associated with a CIV deficiency linked to a region of
chromosome 9q. One gene in this region, SURF-1, which belongs to
the so-called surfeit cluster of six very tightly linked genes that do not
share sequence similarity, was found to display homology with a
previously identified yeast gene (called SHY1, for SURF-1 homolog
in yeast) that encodes a mitochondrial protein required for CIV
expression and respiration (Mashkevich et al., 1997). Dozens of
individuals from unrelated families with a CIV deficiency were
subsequently shown to carrymutations in SURF-1, and further studies
determined that the proteins encoded by SHY1 and SURF-1 are both
required for inserting heme a3 (see Box 2) into CIV (Mashkevich
et al., 1997; Pecina et al., 2004). Similarly, mutations causing distinct
clinical phenotypes – cardioencephalopathies and hepatopathies –
were found in two genes, SCO1 and SCO2, respectively, that are
homologous to a yeast gene (SCO1) required for copper delivery into
CIV (Leary et al., 2004; Papadopoulou et al., 1999; Valnot et al.,
2000a). In linewith these findings, copper supplementationwas found
to restore CIV activity in patient cells carrying mutations in SCO2
(Casarin et al., 2012). Recently, a homozygous mutation in
individuals from two unrelated families displaying ataxia and
muscle hypotonia was found in a gene (FAM36A) homologous to
the yeast geneCOX20 (Szklarczyk et al., 2013), which has previously
been shown to encode a protein that assists membrane insertion and
maturation of the COXII subunit of CIV (Elliott et al., 2012). It was
thus expected that these individuals had defects in the assembly of
CIV, which was confirmed (Bourens et al., 2014; Szklarczyk et al.,
2013). Another well-illustrative example of CIV-based disease that
yeast helped to resolve involves mutations in the geneCOX10, which
encodes a protein with farnesyl transferase activity, which is required
for heme a maturation (Tzagoloff et al., 1993; Valnot et al., 2000b).
The absence of CI in S. cerevisiae has been exploited in the
search for assembly factors of this complex using a comparative
genomics approach with CI-containing yeast species, such as
Yarrowia lipolytica. These studies identified the protein B17.2 and
then its human homolog (B17.2L), which proved to be an essential
chaperone of CI and in which mutations were found in an individual
displaying progressive encephalopathy (Ogilvie et al., 2005).
Similarly, another evolutionarily conserved protein involved in CI
assembly [Ind1 in Y. lipolytica; NUBPL (nucleotide-binding-like)
in humans] that is required for inserting Fe-S centers (see Box 2) in
the peripheral arm of this complex was found, and mutations of this
protein were associated with encephalopathies (Calvo et al., 2010;
Sheftel et al., 2009). These findings from yeast provide new
molecular insights into OXPHOS assembly defects, and into the
complex regulation of this system’s biogenesis, and will likely
reveal more insights in the future.
Diseases characterized by mtDNA maintenance defects
More than 200 mutations in the gene POLG (polymerase gamma),
which encodes the catalytic component of mtDNA polymerase,
have been implicated in various diseases, including progressive
external ophtalmoplegia (PEO), Alper’s syndrome (also called
Alper-Huttenlocher syndrome), myopathy, parkinsonism (a
neurological syndrome characterized by tremor, rigidity and
postural instability that shares symptoms found in Parkinson’s
disease), premature menopause, psychological disorders and ataxia-
neuropathy syndrome (http://tools.niehs.nih.gov/polg) (Hudson and
Chinnery, 2006; Stumpf and Copeland, 2011). These diseases result
from depletion, large-scale deletions and/or point mutations in
mtDNA that compromise mitochondrial function. Owing to its
ability to survive mtDNA loss, a property referred to as ‘petite-
positivity’ shared by only a few yeast species (Bulder, 1964; Chen
and Clark-Walker, 2000), S. cerevisiae is an ideal system in which
to investigate the functional consequences of POLG mutations. In
particular, yeast have helped to distinguish between truly
pathogenic and harmless single-nucleotide polymorphisms
(SNPs), and to determine whether deleterious mutations are
dominant or recessive, and whether they impact POLG stability or
locally disturb domains that are important for the processing and
fidelity of mtDNA replication. For instance, studies in yeast
revealed that the T654A and R656Q POLG mutations are
dominant, slow down replication and result in higher mtDNA
mutability (Baruffini et al., 2006). Mutations affecting the
exonuclease domain of POLG, which is responsible for the
fidelity of mtDNA replication, are generally less detrimental,
causing only modest increases in the rate of mtDNA mutation
(Szczepanowska and Foury, 2010). As with the yeast ATP6 models
of diseases (see above), pathogenic POLG mutations produce a
similar degree of phenotypic severity in both yeast and humans.
Mutations in a small protein of yet-unknown function encoded by
the gene MPV17 was determined as a main cause of mitochondrial
DNA depletion syndrome (MDS), which predominently affects the
liver and eventually induces neurological degeneration (Spinazzola
et al., 2006). Its yeast homolog, SYM1, is required for ethanol
tolerance and for maintaining the mitochondrial morphology
under heat stress (Trott and Morano, 2004). The human MPV17
gene can complement sym1Δ deletion strains, indicating functional
conservation (Trott and Morano, 2004). Although the loss of SYM1
leads to a higher production of ρ−/ρ0 petites lacking functional
mtDNA, this effect is rather mild, indicating that MPV17-based
diseases possibly have an origin other than a failure in mtDNA
propagation (Dallabona et al., 2010).
Diseases caused by defects in mitochondrial protein import
Because most mitochondrial proteins are encoded by nDNA,
defects in the mitochondrial protein import process can have
widespread effects. Mutations affecting GFER (full name: growth
factor homolog to yeast ERV1 responsible for liver regeneration in
humans) (Di Fonzo et al., 2009) and DPP1 (deafness dystonia
peptide 1) (Aguirre et al., 2006; Jin et al., 1996), two components of
the mitochondrial protein import machinery, were found in
individuals presenting with multiple mitochondrial deficiencies
and a complex clinical phenotype characterized by visual and/or
hearing problems, developmental delay, mental retardation and
myopathy. The yeast homolog of GFER, called Erv1p, participates
in the disulfide relay system (Twin-cys, Fig. 1), which enables
proteins with specific cysteine motifs to be imported into the IMS
(Mesecke et al., 2005). The yeast homolog of DPP1 is one of the
small Tim proteins (Tim8p), which functions to deliver
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hydrophobic polytopic membrane proteins for insertion into the IM
(Rothbauer et al., 2001). Studies in yeast of mutations of GFER
(R194H) (Di Fonzo et al., 2009) and DPP1 (C66W) (Hofmann
et al., 2002) that are found in affected individuals provided evidence
that defects in mitochondrial protein import were responsible for the
disease process. Similarly, individuals with skeletal growth and
development disorders were shown to carry a homozygous mutation
(N76D) in MAGMAS (mitochondrial-associated granulocyte
macrophage colony stimulating factor-signaling gene), a protein
belonging to the PAM (presequence translocase-associated motor)
component of the TIM23 machinery, which is involved in the
delivery of nDNA-encoded proteins into the mitochondrial matrix
(Mehawej et al., 2014) (see Fig. 1). A yeast model of this mutation
provided a strong indication that the disease was indeed caused by
defects in mitochondrial protein import (Mehawej et al., 2014).
Diseases caused by defects in metabolite transport
More than ten different MCF (mitochondrial carrier family)-based
diseases have been described (Palmieri, 2014), of which several have
been molecularly characterized by utilizing yeast. For instance,
mitochondrial dysfunction was suspected to underlie high levels in
urine of 2-hydroxyglutaric and of Krebs cycle intermediates in
individuals displaying agenesis of the corpus callosum (see Box 2)
and severe neurodevelopmental problems (Edvardson et al., 2013).
Whole-exome sequencing of these individuals revealed two
mutational changes (G130D and R282H) in highly conserved
positions of the gene encoding the mitochondrial citrate transporter
(SLC25A1). Subsequent studies revealed that the corresponding
mutations in S. cerevisiae impaired respiratory growth owing to
defects in the transport of citrate (see Box 2) across the IM, leaving
little doubt as to their pathogenicity. Similarly, the use of a
S. cerevisiae model yielded evidence that an A15V mutation in
SLC25A15 found in an individual with hyperornithinemia-
hyperammonemia-homocitrullinuria (HHH) syndrome (see Box 2)
exerts its deleterious effects by dramatically reducing the transport of
ornithine (see Box 2) into mitochondria (Ersoy Tunali et al., 2014).
Studies in this yeast have also defined the consequences of several
mutations in isoform-1 of the ADP/ATP translocase [adenine
nucleotide transporter isoform 1 (ANT1)] that have been associated
with various diseases, including autosomal dominant PEO and
hypertrophic cardiomyopathy (Kaukonen et al., 2000; Liu and Chen,
2013). Some mutations (e.g. A137D) almost entirely abolish the
nucleotide transport activity of the yeast ANT1 ortholog (Anc2),
whereas others (A128P,M114P) favorATP/ATPhomo-exchange and
thereby compromise oxidative phosphorylation because of a lack of
ADP within the organelle. Given the central role of mitochondria in
metabolism, yeast are likely to be a powerful tool for continuing to
explore the molecular basis of metabolic disorders.
Diseases caused by defects in mitochondrial dynamics
With the help of yeast studies, several human diseases have been
associated with defects in mitochondrial fusion and fission (Chan,
2012). Approximately 60 mutations in MNF2, which encodes a
protein involved in OM fusion, have been found in individuals
presenting with Charcot-Marie-Tooth disease type 2A (CMT2A),
which is characterized by axonal degeneration of peripheral nerves
and muscle weakness (Cartoni and Martinou, 2009; Zuchner et al.,
2004). Some of these mutations (e.g. I213T) result in fragmented
and aggregated mitochondria when introduced in the yeast
homologous gene (FZO1), whereas others have only negligible
effects in yeast, indicating possible mechanistic differences in OM
fusion between yeast and humans (Amiott et al., 2009). Defects in
IM fusion have been implicated in optic atrophy type 1 (OPA1), a
dominantly inherited optic neuropathy that features progressive loss
in visual acuity (Votruba et al., 1998). Similar symptoms are found
in Leber hereditary optic neuropathy (LHON), which is caused by
mutations in mtDNA-encoded CI subunits, suggesting that
mitochondrial dysfunction could be involved in OPA1 (Johnston
et al., 1979; Kjer et al., 1983). Sequences from the chromosomal
region to which OPA1-causing mutations map exhibit homology to
a yeast gene that encodes a dynamin-related protein essential for
mtDNAmaintenance (Msp1p in Saccharomyces pombe; Mgm1p in
S. cerevisiae) (Jones and Fangman, 1992; Pelloquin et al., 1999).
This homology helped resolve the structure of the OPA1 gene and
to identify numerous OPA1 mutations (including frameshift,
missense, deletions and insertions) that segregated with the
disease, thereby also demonstrating a role for mitochondria in
retinal ganglion cell pathophysiology (Alexander et al., 2000).
Further studies showed that Mgm1p (OPA1) is a mitochondrial
GTPase involved in the fusion of mitochondrial IMs (Ehses et al.,
2009; Griparic et al., 2007; Sesaki et al., 2003; Song et al., 2007;
Wong et al., 2003). Only one mutation affecting mitochondrial
fission has been associated with human disease thus far:
encephalopathy with optic atrophy caused by the A395D variant
of the dynamin-like DRP1 protein (Waterham et al., 2007). Its yeast
homolog (Dnm1p) localizes and oligomerizes at restricted sites on
the surface of mitochondria, suggesting a dynamin-like contractile
mechanism for mitochondrial fission (Fukushima et al., 2001;
Ingerman et al., 2005; Mears et al., 2011). Modeling this pathogenic
mutation in yeast prevented the oligomerization of Dnm1p (DRP1)
owing to its decreased hydrolysis of GTP, suggesting this as a
potential mechanism of disease.
Diseases caused by defects in mitochondrial protein quality control
Hereditary spastic paraplegia (HSP) constitutes a genetically and
clinically heterogeneous group of neurodegenerative disorders
characterized mainly by progressive lower-limb weakness,
spasticity and decreased vibratory sense (Harding, 1983). In 1998,
an autosomal recessive form of HSP was associated with mutations
in a gene (SPG7) encoding a protein (paraplegin) with strong
similarities to the two homologous subunits of the yeast m-AAA
protease [called Afg3 (Yta10) and Rca1 (Yta12)] (Casari et al.,
1998). This protease controls the formation of the respiratory chain
complexes (Arlt et al., 1998). Like its cognate yeast proteins,
paraplegin was shown to localize to mitochondria, and loss-of-
function mutations led to ragged-red fibers, a hallmark of
mitochondrial disorders, and to OXPHOS defects (Casari et al.,
1998). A homology search yielded two paraplegin-related genes,
AFG3L2 and YME1L1, presumed to be the human orthologs of the
yeast genes encoding Afg3p and the protein that constitutes the i-
AAA protease (Yme1p), respectively (Banfi et al., 1999; Coppola
et al., 2000). Paraplegin co-assembles with AFG3L2, and this
interaction is required for the proper expression of CI (Atorino et al.,
2003). Mutations in AFG3L2 cause autosomal dominant
spinocerebellar ataxia type 28 (SCA28), a neurological disorder
caused by Purkinje-cell degeneration (Di Bella et al., 2010). The
human SPG7-AFG3L2 complex rescued yeast strains lacking Rca1p
and Afg3p, demonstrating functional conservation and providing a
simple assay to evaluate the functional consequences of SPG7 and
AFG3L2 mutations found in affected individuals (Bonn et al., 2011;
Di Bella et al., 2010). Many of these mutations were unable to
restore respiratory competence in m-AAA-deficient yeast strains,
providing additional evidence for their deleterious nature in humans
(Di Bella et al., 2010).
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Diseases caused by defects in cardiolipin synthesis and remodeling
Cardiolipin (CL) is a mitochondrial-specific lipid that mostly
localizes to the IM, where it is synthesized (Schlame and Haldar,
1993; Schlame et al., 2000). Studies in yeast have defined howCL is
synthesized and remodeled to maintain a homogenous and highly
unsaturated acyl-chain composition, and how mitochondria are
influenced by defects in these processes (Claypool, 2009; Joshi
et al., 2009; Mileykovskaya and Dowhan, 2009). Yeast strains that
fail to synthesize CL respire poorly and can neither organize the
mitochondrial energy-transducing enzymes into supercomplexes
(i.e. the respirasome) nor promote their association with the ADP/
ATP translocase (ANT), indicating that CL is required for the
formation and/or stability of these multi-complex assemblies. As a
consequence, the mitochondrial membrane potential (ΔΨ) is
decreased, which negatively affects the import of numerous
proteins into the matrix and IM (Joshi et al., 2009). Moreover, CL
interacts with components involved in IM fusion (Mgm1p) and
mitochondrial fission (Dnm1p), and the loss of these interactions
possibly contributes to the abnormal mitochondrial morphologies
observed in yeast strains lacking CL (Ban et al., 2010; DeVay et al.,
2009; Montessuit et al., 2010).
Given the importance of CL for mitochondrial structure and
function, it is not surprising that defects in the synthesis and
remodeling of this lipid are associated with various disorders (Chicco
and Sparagna, 2007). One such disease, Barth syndrome (BTHS), is
caused bymutations in the human gene TAZ, which encodes tafazzin,
an acyl transferase involved in the remodeling of CL (Barth et al.,
1983; Schlame and Ren, 2006). BTHS is an X-linked disease
exhibiting cardiac and skeletal myopathies, delayed growth until
puberty, and increased susceptibility to bacterial infections due to
cyclic neutropenia (see Box 2). Individuals with BTHS are
characterized by pleiotropic respiratory defects (Barth et al., 1996),
possibly because of impaired respirasome stability (McKenzie et al.,
2006), have low levels of CL, and accumulate monolysocardiolipin
(MLCL), an intermediate in the CL remodeling pathway that lacks an
acyl chain, in various tissues and cells (Schlame et al., 2003;
Valianpour et al., 2005). Yeast strains lacking Taz1p (taz1Δ), the
homolog of tafazzin, also accumulate MLCL with a concurrent
decrease in CL (Claypool et al., 2006, 2011; Gu et al., 2004; Testet
et al., 2005; Vaz et al., 2003). These strains display a slow growth
phenotype on respiratory substrates at 37°C and decreased
respirasome stability (Brandner et al., 2005; Gu et al., 2004; Vaz
et al., 2003), providing a simple assay to test the functional
consequences of mutations found in individuals with BTHS. Most
of thesemutations were found to impair CL expression in yeast owing
to mislocalization in the matrix or rapid degradation of the mutated
protein (by the i-AAA protease), confirming their deleterious nature
(Claypool et al., 2006, 2011). Yeast Taz1p assembles into distinct
high-molecular-weight complexes containing various subunits of
ATPsynthase andCIII,ANT, and as-yet-unidentifiedbindingpartners
(Claypool et al., 2008). Future studies should help to reveal howTaz1p
(tafazzin) influences mitochondrial functions in normal and
pathological conditions.
Molecular insights from yeast models with translational
potential
As discussed below, several approaches in yeast have been used to
unravel potential strategies for treating mitochondrial disorders.
This model organism offers simple readouts, such as the common
respiratory growth defect observed in yeast models of mitochondrial
disease, to enable large-scale screens for genetic suppressors
(Box 4) and chemicals able to rescue mitochondrial dysfunction.
Even when mitochondrial dysfunction is severe enough to abolish
respiratory growth, yeast offers the unique advantage that such
mutants can be kept alive and propagated on fermentable substrates
for their use in suppressor screens. Forward chemical genetic
approaches can also be performed in yeast to uncover potential
chemical targets (St Onge et al., 2012).
New insights from metabolic suppression studies
A popular suppressor genetics method in yeast aims to identify genes
that, when overexpressed, rescue a mutation in another gene. This can
be done using libraries of yeast genes cloned into multicopy plasmids.
Unexpectedly, overexpressing the gene encoding Odc1p, a
mitochondrial carrier that transports Krebs cycle intermediates,
compensates for the lack of a protein (Fmc1p) involved in the
assembly of CV (Schwimmer et al., 2005). Although the CV
assembly remained defective, artificially increasing the levels of
Odc1p (by tenfold) in fmc1Δ yeast substantially stimulated respiration
and ATP production through substrate-level phosphorylation in
mitochondria. The overexpression of Odc1p also rescued mutant
strains lacking the yeast homolog of the humanMPV17 gene (SYM1)
implicated in diseases characterized by mtDNA loss in the liver
(Dallabona et al., 2010). Taken together, these studies signify that
metabolic suppression is a promising approach for generating
therapeutic leads for mitochondrial diseases.
Suppressors of disease-causing mt-tRNA mutations
Given the sequence and structural similarities between some
human and yeast mt-tRNAs, yeast has been used to model
pathogenic base substitutions in these molecules, notably in
tRNALeu(UUR), which attaches the amino acid leucine (Leu)
(Montanari et al., 2008). Some of these mutations severely affect
yeast respiratory growth, providing a phenotype to use in
multicopy suppressor gene screens. Several factors involved in
mitochondrial protein synthesis have been identified using this
strategy, including the translation factor EF-Tu (TUFM in humans)
and various (cognate and non-cognate) aminoacyl tRNA
synthetases (aa-RSs; see Box 2) (Feuermann et al., 2003;
Montanari et al., 2010). The suppressor activity of these factors
was also observed in human cells carrying similar mutations (Park
et al., 2008; Sasarman et al., 2008; Rorbach et al., 2008; Li and
Guan, 2010). Interestingly, after the introduction of point
mutations that inactivate their tRNA charging function, aa-RSs
maintained their suppressor activity, which indicates that the
mutated mt-tRNAs recover their functionality likely owing to
chaperone-like RNA-protein interactions (Francisci et al., 2011).
Short regions of less than 70 amino acids near the C-terminus of
aaRSs were sufficient to improve mitochondrial translation, both
in yeast and human cells with defective mt-tRNAs. These findings
hold promise for the development of peptide-based therapies
against diseases induced by mutations in mt-tRNAs.
Box 4. Genetic suppression
In genetic suppression, a mutant phenotype is reversed by the effects of
a mutation at a locus distinct to that of the original mutation. The
suppressor mutation can be located: (1) within the same gene as the
primary (target) mutation, at the same or at a different nucleotide position
(intragenic suppression); (2) in a different gene of the same genome
(intergenic suppression); or (3) in the case of a mitochondrial phenotype,
within another genome (intergenomic suppression), since two different
genomes control mitochondrial function.
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Genetic suppressors of BCS1-based disorders
Yeast has also been used to explore potential mechanistic strategies
to rescue Björnstad and GRACILE (BCS1-based) syndromes
(Ostojic et al., 2013). The former is a relatively mild disease
characterized by twisted hairs (pili torti) and hearing problems
(Hinson et al., 2007), whereas the latter is a much more severe
disorder characterized by growth retardation, aminoaciduria,
cholestasis (see Box 2), iron overload, lactic acidosis and early
death, sometimes before birth (Visapaa et al., 2002). The BCS1
protein belongs to the large and evolutionarily conserved AAA
protein family, characterized by the presence of a typical AAA region
involved in ATP binding and hydrolysis. It is required to incorporate
Rieske iron sulfur protein (Rip1) into CIII (Nobrega et al., 1992;
Wagener et al., 2011). When modeled in yeast Bcs1p, several
pathogenic mutations in the AAA region of human BCS1 were
shown to prevent respiration in yeast owing to a blockade in the
assembly of CIII (Ostojic et al., 2013). Unexpectedly, Rip1 assembly
was restored in these bcs1 yeast mutants owing to secondary
mutations that reduce the ATP hydrolytic activity of CV while
maintaining a sufficient level of ATP synthesis to sustain respiratory
growth. It was reasoned that by reducing the ATP hydrolysis of CV,
the suppressors increase the organellar concentration of ATP and
thereby enable the mutated BCS1 protein to reach sufficient ATP
hydrolytic activity (Ostojic et al., 2013). This hypothesis was
supported by in vitro assays showing that BCS1 hydrolytic activity
returned to normal levels by increasing the concentration of ATP
(Ostojic et al., 2013). This genetic interaction betweenBCS1 andATP
synthase suggests that the AAA region serves not only to provide the
BCS1 protein with the energy required to accomplish its chaperone
function, but also as a sensor of theATP:ADP ratio inmitochondria to
adjust the production of CIII according to the cell’s metabolic state.
This studyelegantly identified the intra-mitochondrial pool of adenine
nucleotides as a potential target for improving the condition of
patients suffering from defects in BCS1, and possibly in other AAA
proteins involved in mitochondrial biogenesis (such as m-AAA).
Genetic suppressors of ANT-based disorders
Given the importance of ANT (adenine nucleotide transporter) for
mitochondrial physiology, not surprisingly, mutations or altered
expression of this protein result in various human diseases, such as
adPEO (autosomal dominant progressive external ophthalmoplegia),
cancer, FSHD (facioscapulohumeral muscular dystrophy) and
Senger’s syndrome, which is characterized by cardiac hypertrophy,
mitochondrial myopathy, cataracts and lactic acidosis (Liu and Chen,
2013). Studies in yeast have suggested that human pathogenic
mutations in ANT1 (isoform 1 of ANT) might not only cause the
defective exchange of adenine nucleotides across the mitochondrial
IM but also inducemitochondrial biogenesis defects, thereby severely
compromising yeast cell viability (even in fermentable media) owing
to the partial uncoupling of the mitochondrial IM (Liu and Chen,
2013; Wang et al., 2008). Interestingly, mutations and chemicals that
reduce cytosolic protein synthesis substantially improve the viability
of yeast models of ANT1-based diseases and suppress some of their
associated mitochondrial phenotypes, such as the loss of mtDNA
integrity. These findings indicate that mutations in ANT1 can lead to
general cellular protein stress due to a reduced capacity of the
mitochondria to import nDNA-encoded proteins. They highlight
cytosolic protein synthesis as a potential therapeutic pathway for
ANT1-based diseases and possibly for other disorders that affect the
delivery of proteins into the organelle either directly or indirectly by
altering the proton pumping activity or the coupling efficiency of the
OXPHOS system.
Genetic suppressors of mtDNA maintenance defects
Genetic suppressors have uncovered potential intervention points for
diseases caused by decreased mtDNA content. One approach used
mutations in various cellular systems (e.g. ANT, F1-ATPase) that
convert S. cerevisiae into a ‘petite-negative’ yeast unable to survive
without mtDNA (Chen and Clark-Walker, 2000). Interestingly,
genetic perturbations in nutrient-responsive signaling pathways that
restored petite-positivity proved to increase the health of yeast cells
lacking mtDNA (Garipler and Dunn, 2013; Garipler et al., 2014).
Other studies have shown that increasing the availability of
mitochondrial dNTP [a well-known limiting factor in mtDNA
replication (Lebedeva and Shadel, 2007)], either by overexpressing
the large subunit of ribonucleotide reductase (Rnr1p) or by deleting a
gene encoding a protein inhibitor of Rnr1p [Sml1p (suppressor of
Mec1 lethality)], significantly suppressed the instability of the
mitochondrial genome in yeast strains bearing mutations in the
mitochondrial DNA polymerase gene mip1 (Baruffini et al., 2006;
Zhao et al., 1998).
Pharmacological suppressors
Yeast has been proposed as a pharmacological model to identify
drugs that are active against mitochondrial diseases (di Rago et al.,
2007; Schwimmer et al., 2006). Although this approach is fairly
recent, a number of fruitful studies have been described, which we
briefly review here.
The first such study used a yeast model (fmc1Δ, described above)
that phenotypically resembles diseases caused by deficiency in fully
assembledATP synthase (Couplan et al., 2011). The fmc1Δ cells were
spread on solid respiratory medium, on which they grow very slowly,
and were then exposed to filters spotted with individual drug
compounds. After a few days of incubation, active compounds were
identified by the appearance of a halo of enhanced growth around the
corresponding filters (see Fig. 4 for an example). This method allows,
in one simple experiment, the testingofnumerous compounds across a
large range of concentrations, owing to their diffusion in the growth
medium – a powerful design for assessingwhen a drug is active at low
concentrations while toxic at higher ones. This screen used, among
others, thePrestwickChemical Library, a collection ofdrugswith high
bioavailabilityand forwhich toxicitystudies have alreadybeen carried
out in humans; therefore, active compounds from this library can
directly enter drug optimization programs.
Among positive hits that improved respiratory growth of fmc1Δ
yeast was chlorhexidine (CH), a well-known antiseptic (Couplan
et al., 2011). This drug had a remarkable suppressor activity in
fmc1Δ yeast, with a substantial (more than twofold) increase in
mitochondrial respiration and ATP synthesis due to a better
expression of OXPHOS enzymes, which was not observed in
wild-type yeast treated with CH. Additionally, upon treatment with
CH, the fmc1Δ cells recovered the ability to form mitochondrial
cristae and no longer displayed inclusion bodies formed by the
aggregation in the mitochondrial matrix of unassembled subunits of
CV (Couplan et al., 2011). In a secondary screen, CH was also
shown to rescue yeast models of diseases [NARP (neuropathy ataxia
retinitis pigmentosa), MILS (maternally inherited Leigh syndrome)]
caused by mutations in the mitochondrial ATP6 gene. This drug was
next tested in human cybrid (cytoplasmic hybrid; Box 2) cell lines
that were nearly homoplasmic (Box 2) for one of these mutations
(T8993G), using a glucose-deprived medium to force the cells to
rely on OXPHOS rather than glycolysis (Box 2). A clear dose-
dependent improvement of NARP cybrid survival was observed,
whereas the growth of wild-type cybrids remained unchanged in the
presence of CH.
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Another drug that markedly improved the respiratory growth of
fmc1Δ yeast, and which also proved therapeutic in patient-derived
T8993G cybrids, was sodium pyrithione (NaPT) (Aiyar et al.,
2014). The pathway(s) through which NaPT rescues ATP synthase
deficiencies were investigated by systematic chemical-genomic
profiling using the yeast genome-wide deletion collection. In this
approach, the pronounced sensitivity of haploinsufficient,
heterozygous deletion mutants to a chemical can indicate cellular
functions and proteins involved in the chemical’s mechanism of
action. The most sensitive mutants included tim17Δ/TIM17 and
tim23Δ/TIM23, which involve essential components of the highly
conserved TIM23 translocase complex of the mitochondrial IM
(Dolezal et al., 2006; Hoogenraad et al., 2002) (Fig. 1). The
sensitivity of these mutants to NaPT was far greater than observed
for many previously profiled compounds, indicating that the
chemical-genetic interaction between NaPT and TIM23 is highly
specific. In vitro assays revealed that NaPT partially compromised
the import of proteins by TIM23 machinery into the matrix, whereas
its lateral sorting activity to the IM was enhanced. The therapeutic
effects of modulating TIM23-mediated import in this precise
manner were confirmed by overexpressing the regulatory subunit
Tim21p, which affects import in a similar way to NaPT (Chacinska
et al., 2009; Popov-Celeketic et al., 2008). Tim21p overexpression
substantially restored the respiratory capacity of fmc1Δ yeast
through improved activity and expression of electron transport
chain (ETC; Box 2) complexes and ATP synthase, and
overexpression of its human homolog TIM21 also rescued human
T8993G cybrids. Although a general inhibition of TIM23 would be
detrimental, these findings suggest that a slight modulation of its
activity could be beneficial in the context of mitochondrial
dysfunction. This study also fits with recent reports indicating that
downregulating TIM23-mediated protein import can be used as a
stress response to maintain protein homeostasis in mitochondria
(Nargund et al., 2012; Rainbolt et al., 2013). Because of the central
role of the TIM23 pathway in mitochondrial function and
biogenesis, its therapeutic potential could possibly extend to other
types of mitochondrial dysfunction.
A similar screening assay was developed for Friedreich’s ataxia
(FRDA), which is a common autosomal recessive degenerative
disease resulting from a GGA trinucleotide expansion within an
intron (Box 2) of a nuclear gene encoding a protein (frataxin) that
controls mitochondrial iron homeostasis (Rotig et al., 1997).
Using a yeast strain lacking the orthologous gene, YFH1 (yeast
frataxin homolog) (Foury and Cazzalini, 1997), a number of
potential compounds for the treatment of FRDA that function via
an as-yet-unknown mechanism were identified (Cotticelli et al.,
2012). Finally, a recently published yeast-based assay was
employed to screen for small molecules that increase the
mitochondrial membrane potential and cellular ATP levels
(Montague et al., 2014). Fourteen positive hits were isolated
from a collection of 13,680 compounds, of which several were able
to increase ATP levels in hepatocytes and fibroblasts. Genomic
and mitochondrial proteomic analyses indicate that the drug
response in the human cells involves key factors controlling
metabolic functions such as PGC-1α (peroxisome proliferator-
activated receptor gamma coactivator 1-alpha), which is an animal
transcriptional coactivator that regulates genes involved in energy
metabolism. Taken together, these studies validate the use of
yeast-based models for effective high-throughput screening
approaches aimed at identifying drugs with the potential to
restore mitochondrial function and to treat mitochondrial
disorders.
Plating of cells as a
dense layer on solid
respiratory medium
 
Culture of a respiratory-deficient
yeast model of mitochondrial
disease in fermentable medium
Depose paper
discs
Chemical
compounds 
 
Incubation 
Positive
hit
Spotting on
the discs
Example
A 
B 
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D 
E 
Negative
control 
Fig. 4. A yeast-based assay to identify drugs that are active against
mitochondrial disorders. (A) A respiratory-deficient yeast model of a
mitochondrial disease is grown in glucose. (B) Subsequently, yeast cells
are spread onto a solid medium containing a non-fermentable substrate
(glycerol), on which they grow very poorly. (C) Small sterile filters are
placed on the agar surface and (D) spotted with compounds from a
chemical library; the plate is then incubated for several days. (E) After
incubation, active drugs that improve mitochondrial function in the yeast
disease model result in the appearance of a halo of enhanced growth
around the corresponding filters.
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Conclusions
Although considerable progress in understanding mitochondrial
function has been made during the last decades, much remains to
be learned about mitochondrial processes and components, their
regulation and their interplay with the rest of the cell. Owing to the
exceptionally thorough annotation of its genome, its tractability for
manipulating mitochondrial and nuclear genes, and the high
conservation of mitochondrial function, S. cerevisiae will
continue to be an essential model system for this major research
challenge.
Expanding our comprehension of mitochondrial biology further
will be instrumental to better define human diseases caused by
mitochondrial dysfunction. Considering the huge complexity of
human mitochondria, with approximately 1500 proteins, it is likely
that the list of mitochondrial diseases (<200 have been described so
far) will rapidly increase. Although some functions fulfilled by
human mitochondria do not exist in yeast (for example, calcium
storage and apoptosis), human and yeast mitochondrial proteomes
are so similar that yeast is very well-suited to determine the primary
effects on mitochondrial energy transduction and physiology of
disease-linked mutations (Schwimmer et al., 2006).
Those diseases associated with mtDNA variants, the list of
which is rapidly expanding, are particularly challenging to study
owing to factors like heteroplasmy (Box 2), complex inheritance,
variable penetrance and interactions with (e.g. nuclear) modifier
genes, which makes it difficult to verify their pathogenicity,
let alone understand how they lead to disease. The ability to
introduce mtDNA mutations in a defined nuclear genetic
background and the absence of stable heteroplasmy in S.
cerevisiae allows human mtDNA variants to be studied in
isolation, which has often proven useful in elucidating the
mechanistic basis of their pathogenicity. Developing mtDNA
genetic tools in the yeast Y. lipolytica would be of great interest to
model pathogenic mutations of mtDNA that affect the CI, an
essential energy-transducing system not present in S. cerevisiae
that is often implicated in human disorders (see Fig. 2).
One of the most devastating aspects of mitochondrial diseases is
the dearth of effective therapeutic strategies. Here also, yeast could
provide a tremendous help by enabling straightforward and fairly
easy selection of correcting mechanisms, by way of genetic
suppressors and chemical screening. Although fairly recent, this
approach has already pointed to the therapeutic potential of peptide-
based therapies, metabolic suppression or bypasses, and targeting
the regulation of pathways not necessarily implicated in the disease.
Such revelations underscore the power of yeast models and system
approaches for unearthing novel and otherwise unpredictable
candidate intervention points for the treatment of mitochondrial
disorders. As a unicellular organism, yeast cannot be used to model
a disease at the scale of an organ or an intact complex multicellular
organism. However, modeling mitochondrial dysfunction at the
multi-organ level is now possible in invertebrate (e.g.
Caenorhabditis elegans) as well as vertebrate (e.g. Danio rerio)
animals, in which, like in yeast, most biological processes involved
in mitochondrial function are conserved. These systems offer a way
to test whether molecular findings can be moved from yeast into
translational research.
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H.s.  genes S.c.  genes Molecular function within mitochondria Mitochondrial Diseases % 
id
H.s. /S.c. 
protein length
SDHA SDH1 flavoprotein subunit of succinate dehydrogenase Leigh syndrome 63 664/660
SDHB SDH2 Fe/S subunit of succinate dehydrogenase paraganglioma 63 280/266
SDHC SDH3 membrane anchor subunit of succinate dehydrogenase paraganglioma 23 169/198
SDHD SDH4 membrane anchor subunit of succinate dehydrogenase paraganglioma 16 159/181
SDHAF1 YDR379C-A (SDH6) involved in SDH assembly leukoencephalopathy 20 115/79
SDHAF2 EMI5 (SDH5) SDHA flavination paraganglioma 35 166/162
DLAT LAT1 Dihydrolipoamide acetyltransferase component (E2) of the PDC hypotonia, neurological syndrome 30 647/482
DLD DLD1 D-lactate dehydrogenase encephalopathy 13 509/587
SUCLA2 LSC2 Beta subunit of succinyl-CoA ligase encephalomyopathy, mtDNA depletion syndrome 42 405/427
SUCLG1 LSC1 Alpha subunit of succinyl-CoA ligase encephalomyopathy, mtDNA depletion syndrome 53 346/329
PDHB PDB1 E1 beta subunit of the pyruvate dehydrogenase (PDH) complex neurological syndrome 56 359/366
PDHX PDX1 E3-binding protein of the mitochondrial pyruvate dehydrogenase complex neurological syndrome 18 501/410
ACO2 ACO1 aconitase cerebellar degeneration 66 778/780
IDH2 IDH2 subunit of mitochondrial NAD(+)-dependent isocitrate dehydrogenase Maffucci syndrome, encephalopathy 17 452/362
IDH3B IDH1 subunit of mitochondrial NAD(+)-dependent isocitrate dehydrogenase retinitis pigmentosa 43 385/360
OGDH KGD1 subunit of the mitochondrial alpha-ketoglutarate dehydrogenase complex metabolic acidosis, hypoglycemia 44 1023/1014
FH FUM1 fumarase; converts fumaric acid to L-malic acid in the TCA cycle encephalopathy 62 510/488
PDHA1 PDA1 Link between TCA and OXPHOS, catalyzing conversion of pyruvate in acetyl-CoA Leigh syndrome, X-linked; Pyruvate dehydrogenase E1-alpha deficiency 44 390/420
UQRC2 COR2 subunit of ubiquinol cytochrome-c reductase (complex III) metabolic acidosis 20 453/368
UQCRB QCR7 subunit of ubiquinol cytochrome-c reductase (complex III) metabolic acidosis 31 111/127
UQCRQ QCR8 subunit of ubiquinol cytochrome-c reductase (complex III) neurological defect 18 82/94
CYC1 CYT1 cytochrome c1, catalytic subunit of complex III metabolic acidosis 45 325/309
BCS1 BCS1 protein required for the assembly of the FeS subunit into complex III encephalopathy with hepathic failure,  Gracile syndrome 45 419/456
HCCS CYC3 cytochrome c heme lyase, attaches heme to apo-cytochrome c microphtalmia 31 268/269
CYCS CYC1, CYC7 cytochrome c hyperglycemia, thrombocytopenia 59 105/109
UQCC2 CBP6 protein required for translation of the COB mRNA mental retardation 13 126/162
LYRM7 (MZM1L) MZM1 protein required for the assembly of the FeS subunit into complex III encephalopathy 21 104/123
COX4I2 COX5 subunit  of cytochrome c oxidase (complex IV) exocrine pancreatic deficiency 15 171/153
COX6B1 COX12 subunit of cytochrome oxidase (complex IV) cardioencephalomyopathy 40 86/83
COX10 COX10 heme A:farnesyltransferase Leigh syndrome, cardiomyopathy 28 443/462
COX15 COX15 protein required for the hydroxylation of heme O to form heme A Leigh syndrome, cardiomyopathy 33 410/486
COX20 COX20 required for proteolytic processing of Cox2p and its assembly into cytochrome c oxidase hypotonia, cerebellar ataxia 12 118/205
SCO1 SCO1 deliver copper to complex IV Leigh syndrome, cardiomyopathy 30 301/295
SCO2 SCO2 transfer of Cu or cysteine reduction in Cox2p Leigh syndrome, cardiomyopathy 27 266/301
SURF1 SHY1 involved in complex IV assembly Leigh syndrome 22 300/389
COX14-(C12ORF62) COX14 involved in translational regulation of Cox1p and assembly of complex IV metabolic acidosis 13 57/70
PET100 PET100 protein required for the assembly of complex IV Leigh syndrome 17 73/111
COA5-(C2ORF64) PET191 protein required for assembly of cytochrome c oxidase cardiomyopathy 18 74/108
LRPPRC PET309 specific translational activator for the COX1 mRNA Leigh syndrome 11 1394/965
Nuclear genes
Respiratory Complex II & TCA cycle
Respiratory Complex III
Respiratory Complex IV
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H.s.  genes S.c.  genes Molecular function within mitochondria Mitochondrial Diseases % 
id
H.s. /S.c. 
protein length
TACO1 YGR021w unknown Leigh syndrome, cardiomyopathy 23 297/290
ATP5A1 ATP1 alpha subunit of the F1 sector of mitochondrial F1F0 ATP synthase encephalopathy 69 553/545
ATP5E ATP15 epsilon subunit of the F1 sector of mitochondrial F1F0 ATP synthase cardiomyopathy, neuropathy 24 51/62
ATPAF2 ATP12 assembly of F1 portion of ATP synthase cardiomyopathy, metabolic acidosis 18 328/289
ANT1, SLC25A4 AAC3, AAC2, AAC1 ATP/ADP carrier ophthalmoplegia, cardiomyopathy 49 298/307
SLC25A3 PIC2 inorganic phosphate carrier sideroblastic anemia, cardiomyopathy 38 362/300
SLC25A1 CTP1 citrate carrier encephalopathy 34 311/299
SLC25A12, A23, A22 AGC1 acts both as a glutamate uniporter and as an aspartate-glutamate exchanger epileptic encephalopathy 25 678/902
SLC25A15 ORT1 exports ornithine from mitochondria as part of arginine biosynthesis HHH syndrome 38 301/292
SLC25A19 TPC1 mediates uptake of the essential cofactor thiamine pyrophosphate (ThPP) into microcephaly 25 320/314
SLC25A20 CRC1 carnitine transporter neuropathy, cardiopathy, liver dysfunction 29 301/327
SLC25A38 HEM25 Iron transporter, mediates Fe2+ transport across inner mito membrane sideroblastic anemia 27 304/314
ADCK3 (CABC1)/ADCK4COQ8 (ABC1) protein required for ubiquinone biosynthesis cerebellar ataxia and seizures 30 647/501
COQ2 COQ2 para hydroxybenzoate polyprenyl transferase Leigh syndrome, nephropathy, Nephrotic syndrome through CoQ10 biosynthesis disruption 35 371/372
COQ6 COQ6 putative flavin-dependent monooxygenase nephropathy 29 468/479
COQ9 COQ9 protein required for ubiquinone biosynthesis nephropathy, cardiomyopathy, encephalopathy 19 318/260
PDSS1, PDSS2 COQ1 Hexaprenyl pyrophosphate synthetase encephaloneuropathy, Leigh syndrome, nephropathy 25 415/473
TAZ TAZ1 lyso-phosphatidylcholine acyltransferase Barth syndrome (cardiomyopathy and cyclic neutropenia) 19 292/381
ABCB7 ATM1 ATP-binding cassette (ABC) transporter: exports iron-sulfur (Fe/S) clusters to the cytosol anemia, ataxia 41 752/690
ALAS2 HEM1 5-aminolevulinate synthase; catalyzes the first step in the heme biosynthetic pathway anemia, protoporphyria 32 587/548
FXN YFH1 iron chaperone, formation of Fe-S clusters Friedreich Ataxia 25 210/174
ISCU ISU1 scaffolding function during assembly of iron-sulfur clusters, myopathy 55 167/165
NFU1 NFU1 protein involved in iron metabolism in mitochondria encephalopathy 29 254/256
GLRX5 GRX5 glutathione-dependent oxidoreductase sideroblastic anemia 34 157/150
SFXN4 FSF1 predicted to be an alpha-isopropylmalate carrier growth retardation, hypotonia 22 337/327
BOLA3 AIM1 unknown encephalopathy, cardiomyopathy 24 107/118
IBA57 (c1orf69) IBA57 involved in the incorporation of iron-sulfur clusters into mitochondrial aconitase-type proteins encephalomyopathy 18 356/497
LYRM4 ISD11 iron-sulfur cluster biogenesis factor neonatal lactic acidosis 37 91/94
NFS1 NFS1 iron-sulfur cluster assembly lactic acidemia and hypotonia 56 457/497
FDX1L YAH1 iron-sulfur cluster biogenesis myopathy 33 183/172
POLG MIP1 mtDNA polymerase ataxia, ophthalmoplegia, encephalopathy, Alpers syndrome 26 1239/1254
RRM2B § TYMP ribonucleotide-diphosphate reductase (RNR), small subunit ophthalmoplegia, encephalomyopathy, Kearns-Sayre syndrome 55 351/399
MPV17 SYM1 unknown neurohepatopathy 26 176/197
TYMP § ADO1 cytosolic thymidine phosphorylase mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) 35 341/482
Carriers
CoQ biosynthesis
Phospholipids
FeS biogenesis - ROS response
DNA, dNTP synthesis
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H.s.  genes S.c.  genes Molecular function within mitochondria Mitochondrial Diseases % 
id
H.s. /S.c. 
protein length
MRPL12 MNP1 ribosomal protein of the large subunit of the mitochondrial ribosome Growth retardation, neurological distress 32 198/194
MRPS16 MRPS16 ribosomal protein of the small subunit Metabolic acidosis 27 137/121
MRPL3 MRPL9 ribosomal protein of the large subunit cardiomyopathy 26 348/269
MRPL44 MRPL3 ribosomal protein of the large subunit cardiomyopathy 13 332/390
AARS2 ALA1 mitochondrial alanyl-tRNA synthetase cardiomyopathy 37 985/983
DARS2 MSD1 mitochondrial aspartyl-tRNA synthetase leukoencephalopathy 30 645/658
EARS2 MSE1 mitochondrial glutamyl-tRNA synthetase leucoencephalopathy 33 523/536
FARS2 MSF1 mitochondrial phenylalanyl-tRNA synthetase Alpers syndrome 33 451/469
GARS GRS1, GRS2 cytoplasmic and mitochondrial glycyl-tRNA synthase neuropathy, Charcot-Marie-Tooth disease 39 739/690
HARS2 HTS1 mitochondrial histidine-tRNA synthetase Perrault syndrome 40 506/546
KARS MSK1 cytoplasmic and mitochondrial lysine-tRNA synthetase neuropathy,  Charcot-Marie-Tooth disease, deafness 28 597/576
LARS2 NAM2 mitochondrial leucyl-tRNA synthetase Perrault syndrome 4 33 903/894
MARS2 MSM1 mitochondrial methionyl-tRNA synthetase Ataxia, ARSAL syndrome 32 593/575
RARS2 MSR1 mitochondrial arginyl-tRNA synthetase encephalopathy, pontocerebellar hypoplasia 35 578/643
SARS2 DIA4 mitochondrial seryl-tRNA synthetase HUPRA syndrome 29 518/446
TARS2 MST1 mitochondrial threonyl-tRNA synthetase idiopatic inflammatory disease 25 718/462
VARS2 VAS1 mitochondrial and cytoplasmic valyl-tRNA synthetase hypotonia 38 1063/1104
YARS2 MSY1 mitochondrial tyrosyl-tRNA synthetase  MLASA syndrome 30 477/492
MTFMT FMT1 methionyl-tRNA formyltransferase developmental delay, optic atrophy 21 389/401
GFM1 MEF1 mitochondrial elongation factor involved in translational elongation hepatoencephalopathy 51 751/761
TUFM TUF1 mitochondrial translation elongation factor Tu hepatoencephalopathy, cardiomyopathy 54 452/437
TSFM TSF1* mitochondrial translation elongation factor Ts encephalomyopathy, cardiomyopathy, liver failure 21 325/299
C12orf65 YLR281C unknown spastic paraplegia, Leigh syndrome 23 155/166
PUS1 PUS1, PUS2 tRNA:pseudouridine synthase myopathy, MLASA syndrome 25 427/544
MTO1 MTO1 perform the 5-carboxymethylaminomethyl modification of the wobble base in mitochondrial tRNAs cardiomyopathy 42 717/669
TRMU SLM3 (MTO2) tRNA-specific 2-thiouridylase myopathy, deafness 25 421/417
RMND1 YDR282C unknown encephalopathy 17 449/414
CPS1 URA2 bifunctional carbamoylphosphate synthetase/aspartate transcarbamylase urea cycle disorders, neonatal pulmonary hypertension 33 1500/2214
DNAJC19 MDJ2 subunit of the mitochondrial import motor; cardiomyopathy, ataxia 30 116/146
GFER ERV1 oxidase of the disulfide relay system myopathy 26 205/189
HSPD1 HSP60 mitochondrial chaperonin spastic paraplegia 55 573/572
TIMM8A TIM8 chaperone of the subunit Tim23 of the translocase  of the inner mitochondrial membrane deafness, optic atrophy, Mohr-Tranebjaerg syndrome 33 97/87
MAGMAS (TIM16) PAM16 subunit of the translocase of the inner mitochondrial membrane spondylodysplastic dysplasia 35 125/149
SPG7 AFG3 m-AAA metalloprotease spastic paraplegia 36 795/761
AFG3L2 YTA12 (RCA1) m-AAA metalloprotease spastic ataxia, neuropathy 44 797/825
DNM1L-(DRP1) DNM1 dynamin-related GTPase mediating mitochondrial fission encephalopathy 43 736/757
MFN2 FZO1 GTPase mediating OM fusion optic atrophy, neuropathy 14 757/855
OPA1 MGM1 dynamin-related GTPase mediating IM fusion optic atrophy 17 960/881
Translation
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 MT-CYTB  COB (CYTB) catalytic subunit of complex III, cytochrome b exercice intolerance, cardiomyopathy 48 380/385
MT-COX1 COX1 catalytic subunit of complex IV complex IV deficit, deafness, MELAS and Leigh syndromes, myoglobinuria 56 513/534
MT-COX2 COX2 catalytic subunit of complex IV complex IV deficit, deafness, MELAS and Leigh syndromes, myoglobinuria 38 227/251
ATP6 ATP6 Subunit a of the F0 sector of mitochondrial F1F0 ATP synthase NARP and Leigh syndromes, cardiopathy, spastic paraplegia 30 226/259
ATP8 ATP8 Subunit A6L of the F0 sector of mitochondrial F1F0 ATP synthase Hypertrophic cardiomyopathy, Neuropathy 19 68/48
Respiratory complex IV
Databases used to compile this table: UniProt (http://www.uniprot.org/), CilDB (http://cildb.cgm.cnrs-gif.fr/), SGD (http://www.yeastgenome.org/) and 
ORFANET (http://www.orpha.net). All the listed nuclear genes encoded mitochondrial proteins except those marked by §, which are cytosolic 
proteins. The gene marked by * is absent in S. cerevisiae  but present in Schizosaccharomyces pombe H.s., Homo sapiens; S.c., Saccharomyces 
cerevisiae ; % id, percentage identity.
. 
ATP synthase
Mitochondrial genes
Respiratory complex III
Table 1. Yeast homologs of human genes involved in mitochondrial disease
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